Germany Shakes Up Drug Pricing with Confidential Rebates and IRP Ban
Key TakeawaysGermany’s Medical Research Act eliminates international reference pricing (IRP) from its drug pricing framework.
New confidential rebate options aim to protect German...
HUTCHMED Gains Full Approval for ORPATHYS® in NSCLC
Key Takeaways:ORPATHYS® receives full NMPA approval in China for treatment-naïve and previously treated NSCLC patients with MET exon 14 alterations.
Confirmatory Phase IIIb...
PulseSight Begins Phase I Trial for Dry AMD Therapy
Key Takeaways:PulseSight initiates the Phase I trial for PST-611, targeting dry AMD/geographic atrophy.
PST-611 uses non-viral vectorized therapy to regulate iron homeostasis and...
Boehringer Shares Phase III Schizophrenia Trial Results
Key TakeawaysBoehringer Ingelheim reports Phase III iclepertin trial did not meet primary endpoints.
No significant cognitive improvements observed in schizophrenia patients over six...
Eckert & Ziegler Strengthens Global Ac-225 Supply with Key Chinese Partnership
Key TakeawaysEckert & Ziegler secures a €10 million license agreement with Qi Kang Medical (QKM).
Partnership enhances Actinium-225 supply for expanding radiopharmaceutical applications.
...
Terumo and Fujifilm Collaborate to Advance T Cell Expansion for Cell Therapy
Key TakeawaysTerumo Blood and Cell Technologies partners with Fujifilm Irvine Scientific to accelerate T cell expansion.
Fujifilm's PRIME-XV® media integrates with Terumo's Quantum...
Ariceum and ITM Partner to Advance Actinium-225 Supply for Cancer Treatments
Key TakeawaysAriceum Therapeutics and ITM sign a supply agreement for Actinium-225 (Ac-225).
Actinium-225 is critical for developing Ariceum's targeted radiopharmaceutical pipeline, including satoreotide.
...
Er-Kim Partners with MEDICE to Distribute Vafseo® in Central & Eastern Europe
Key TakeawaysEr-Kim and MEDICE sign a distribution agreement for Vafseo® (vadadustat) across eight Central & Eastern European countries.
Vafseo® provides a once-daily treatment...
FDA Clears Ariceum’s 225Ac-Satoreotide for Phase I/II Cancer Trials
Key TakeawaysThe FDA clearance enables Ariceum Therapeutics to commence Phase I/II trials for 225Ac-SSO110.
The trial will focus on treating small cell lung...
Vetter Unveils Next Evolution of V-OVS® Syringe Closure System
Key TakeawaysVetter announces the V-OVS® next syringe closure system, launching in 2027.
New features enhance tamper-evidence, user-friendliness, and compatibility with smaller syringes.
Development...
Carteyva® Receives Breakthrough Therapy Designation in China for LBCL
Key TakeawaysThe Breakthrough Therapy Designation was granted for Carteyva® as a second-line treatment for relapsed or refractory large B-cell lymphoma (r/r LBCL) in...
Preparing for EU HTA Joint Clinical Assessments
Key TakeawaysThe EU HTA Regulation will take effect on January 12, 2025.
Joint Clinical Assessments (JCAs) will begin with innovative cancer and cell...
FDA Expands Approval of JYLAMVO for Paediatric Patients
Key TakeawaysThe FDA approval of JYLAMVO now includes paediatric indications for ALL and pJIA.
JYLAMVO offers a patient-friendly, orange-flavored oral liquid solution.
The...
EU Health Summit 2025: A Roadmap for a Healthier Europe
Key TakeawaysThe EU Health Summit will address critical challenges in European healthcare.
Topics include ageing populations, chronic diseases, and workforce pressures.
The event...
Boehringer Ingelheim Expands Oncology Portfolio with Synaffix ADC Technology
Key TakeawaysBoehringer Ingelheim licenses Synaffix’s ADC technology to enhance its oncology pipeline.
The partnership includes a potential milestone value of $1.3 billion.
The...
